On January 12, 2024, the Board of Directors of NeuBase Therapeutics, Inc. terminated the employment of Dietrich A. Stephan, Ph.D. as Chief Executive Officer of the Company, without cause, and appointed Todd P. Branning, who has served as the Company?s Chief Financial Officer since January 2022, as the Company?s interim Chief Executive Officer, in each case effective as of January 16, 2024. Mr. Branning will continue in his role as the Company?s Chief Financial Officer during his tenure as the Company?s interim Chief Executive Officer. Dr. Stephan is expected to continue to serve on the Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4396 USD | -0.54% | +2.23% | -40.60% |
Mar. 26 | Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading | MT |
Mar. 26 | US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings | MT |
1st Jan change | Capi. | |
---|---|---|
-40.60% | 1.65M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. Announces CEO Changes